Cover Image
市場調查報告書

Johnson & Johnson - 產品平台檢討

Johnson & Johnson - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 208483
出版日期 內容資訊 英文 423 Pages
訂單完成後即時交付
價格
Back to Top
Johnson & Johnson - 產品平台檢討 Johnson & Johnson - Product Pipeline Review - 2016
出版日期: 2016年03月22日 內容資訊: 英文 423 Pages
簡介

本報告網羅製造許多醫療保健產品,並銷售到全球市場的Johnson & Johnson,彙整其研究開發及開發中產品相關資料,及各開發階段,為您概述為以下內容。

目錄

Johnson & Johnson概述

  • Johnson & Johnson概要
  • 主要資訊
  • 主要資料

Johnson & Johnson - 研究發展概要

  • 主要的治療領域

Johnson & Johnson - 開發平台評估

  • 各開發階段平台產品
  • 開發中產品 - 單劑療法
  • 開發中產品 - 聯合治療

Johnson & Johnson - 開發中產品的一覽

  • 後期階段的開發中產品
  • 臨床階段的開發中產品
  • 初期階段的開發中產品

Johnson & Johnson - 藥物簡介

Johnson & Johnson - 開發平台分析

  • Johnson & Johnson - 不同治療分類的開發中產品
  • 按Johnson & Johnson - 標的開發中產品
  • Johnson & Johnson - 不同給藥途徑的開發中產品
  • Johnson & Johnson - 各類型分子的開發平台產品

Johnson & Johnson - 最新的開發平台資訊

Johnson & Johnson - 暫停中的計劃

成為了Johnson & Johnson - 中止開發的開發中產品

Johnson & Johnson - 財務報表

Johnson & Johnson - 所地與子公司

  • 總公司
  • 其他據點及子公司

最近的開發情形

財務交易情勢

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07998CDB

Summary

Global Markets Direct's, 'Johnson & Johnson - Product Pipeline Review - 2016', provides an overview of the Johnson & Johnson's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Johnson & Johnson, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Johnson & Johnson
  • The report provides overview of Johnson & Johnson including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Johnson & Johnson's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Johnson & Johnson's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Johnson & Johnson's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Johnson & Johnson
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Johnson & Johnson's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Johnson & Johnson Snapshot
    • Johnson & Johnson Overview
    • Key Information
    • Key Facts
  • Johnson & Johnson - Research and Development Overview
    • Key Therapeutic Areas
  • Johnson & Johnson - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
    • Pipeline Products - Out-Licensed Products
  • Johnson & Johnson - Pipeline Products Glance
  • Johnson & Johnson - Late Stage Pipeline Products
  • Johnson & Johnson - Clinical Stage Pipeline Products
  • Johnson & Johnson - Early Stage Pipeline Products
  • Johnson & Johnson - Unknown Stage Pipeline Products
  • Johnson & Johnson - Drug Profiles
    • (canagliflozin + metformin hydrochloride XR)
    • bedaquiline fumarate
    • daratumumab
    • ustekinumab
    • bortezomib
    • golimumab
    • tipifarnib
    • (cobicistat + darunavir + emtricitabine + tenofovir alafenamide)
    • (naproxen sodium + sumatriptan succinate)
    • abiraterone acetate
    • canagliflozin
    • esketamine hydrochloride
    • fulranumab
    • guselkumab
    • imetelstat sodium
    • infliximab
    • JNJ-56021927
    • rivaroxaban
    • sirukumab
    • tapentadol hydrochloride IR
    • trabectedin
    • JNJ-54861911
    • (AL-335 + odalasvir + simeprevir)
    • AL-335
    • ALS-8176
    • Cell Therapy for HIV-1 Infection
    • CNTO-3157
    • CNTO-6785
    • erdafitinib
    • JNJ-39393406
    • JNJ-40411813
    • JNJ-42039556
    • JNJ-42847922
    • JNJ-49095397
    • JNJ-53718678
    • JNJ-56022473
    • JNJ-56914845
    • JNJ-872
    • odalasvir
    • ORM-12741
    • quisinostat hydrochloride
    • rilpivirine
    • siltuximab
    • sovaprevir
    • TMC-310911
    • toreforant tartrate
    • CNTO-2476
    • COVA-322
    • telaprevir
    • Vaccine for Prostate Cancer
    • ACH-3422
    • AL-794
    • ALS-8112
    • CNTO-7160
    • EVT-100 Series
    • EVT-103
    • JNJ-18038683
    • JNJ-38877618
    • JNJ-42721458
    • JNJ-47910382
    • JNJ-49122944
    • JNJ-54175446
    • JNJ-55375515
    • JNJ-55920839
    • JNJ-56136379
    • JNJ-61610588
    • JNJ-64052781
    • JNJ-757
    • JNJ-809
    • NVR-3778
    • RV-1162
    • RV-1729
    • TOP-1288
    • Small Molecules for Rhinovirus Infections
    • Small Molecules to Inhibit Viral RNA Polymerase for RSV Infections
    • AL-516
    • CNTO-530
    • COVA-208
    • COVA-420
    • COVA-493
    • COVA-494
    • DiTU
    • flubendazole
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction
    • JNJ-26070109
    • JNJ-26993135
    • JNJ-28307474
    • JNJ-28312141
    • JNJ-28610244
    • JNJ-31020028
    • JNJ-35815208
    • JNJ-375
    • JNJ-39729209
    • JNJ-39933673
    • JNJ-40279486
    • JNJ-40413269
    • JNJ-41477670
    • JNJ-42314415
    • JNJ-42905343
    • JNJ-46778212
    • JNJ-47965567
    • JNJ-5234801
    • JNJ-54416076
    • Monoclonal Antibodies to Inhibit TGF-beta 1 for Fibrosis
    • Monoclonal Antibody for Autoimmune Diseases
    • Nucleozin
    • Recombinant Peptides to Block Kv1.3 Channel for Autoimmune Diseases
    • Recombinant Protein-1 for Undisclosed Indication
    • Recombinant Protein-2 for Undisclosed Indication
    • Recombinant Proteins for Inflammatory and Autoimmune Diseases
    • RV-1088
    • S-961
    • Small Molecule to Inhibit Capsid Protein for Hepatitis B
    • Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia
    • Small Molecule to Inhibit FLT3 for AML
    • Small Molecule to Inhibit PDE10A for Schizophrenia
    • Small Molecule to Inhibit Stearoyl-CoA Desaturase-1 for Obesity
    • Small Molecules to Antagonize P2X7 for Central Nervous System
    • Small Molecules to Inhibit FMS for Rheumatoid Arthritis
    • Stem Cell Therapy for Type 1 and Type 2 Diabetes
    • VE-202
    • ALS-2135
    • Cellular Immunotherapy for Solid Tumors
    • Drugs for Cancer
    • Drugs for Prostate Cancer
    • influenza vaccine
    • LCTA-949
    • Peptides to Inhibit Ion Channel for Chronic Pain
    • Recombinant Protein for Inflammatory Bowel Diseases
    • Small Molecule to Inhibit cccDNA for Hepatitis B
    • Small Molecule to Inhibit Kinase for Autoimmune Diseases
    • Small Molecules for Central Nervous System Disorders
    • Small Molecules for Hepatitis B
    • Small Molecules for Lymphoma
    • Small Molecules to Antagonize Androgen Receptor for Castration-Resistant Prostate Cancer
    • Small Molecules to Antagonize CCR2 for Type II Diabetes
    • Small Molecules to Block Cav2.2 Channel for Chronic Pain
    • TMC-207 Back Up
    • VX-353
    • Biologics for Undisclosed Indication
    • JNJ-40346527
    • RV-6153
  • Johnson & Johnson - Pipeline Analysis
    • Johnson & Johnson - Pipeline Products by Target
    • Johnson & Johnson - Pipeline Products by Route of Administration
    • Johnson & Johnson - Pipeline Products by Molecule Type
    • Johnson & Johnson - Pipeline Products by Mechanism of Action
  • Johnson & Johnson - Recent Pipeline Updates
  • Johnson & Johnson - Dormant Projects
  • Johnson & Johnson - Discontinued Pipeline Products
  • Discontinued Pipeline Product Profiles
  • Johnson & Johnson - Company Statement
  • Johnson & Johnson - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Johnson & Johnson, Key Information
  • Johnson & Johnson, Key Facts
  • Johnson & Johnson - Pipeline by Indication, 2016
  • Johnson & Johnson - Pipeline by Stage of Development, 2016
  • Johnson & Johnson - Monotherapy Products in Pipeline, 2016
  • Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016
  • Johnson & Johnson - Partnered Products in Pipeline, 2016
  • Johnson & Johnson - Partnered Products/ Combination Treatment Modalities, 2016
  • Johnson & Johnson - Out-Licensed Products in Pipeline, 2016
  • Johnson & Johnson - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Johnson & Johnson - Pre-Registration, 2016
  • Johnson & Johnson - Filing rejected/Withdrawn, 2016
  • Johnson & Johnson - Phase III, 2016
  • Johnson & Johnson - Phase II, 2016
  • Johnson & Johnson - Phase I, 2016
  • Johnson & Johnson - IND/CTA Filed, 2016
  • Johnson & Johnson - Preclinical, 2016
  • Johnson & Johnson - Discovery, 2016
  • Johnson & Johnson - Unknown, 2016
  • Johnson & Johnson - Pipeline by Target, 2016
  • Johnson & Johnson - Pipeline by Route of Administration, 2016
  • Johnson & Johnson - Pipeline by Molecule Type, 2016
  • Johnson & Johnson - Pipeline Products by Mechanism of Action, 2016
  • Johnson & Johnson - Recent Pipeline Updates, 2016
  • Johnson & Johnson - Dormant Developmental Projects,2016
  • Johnson & Johnson - Discontinued Pipeline Products, 2016
  • Johnson & Johnson, Subsidiaries

List of Figures

  • Johnson & Johnson - Pipeline by Top 10 Indication, 2016
  • Johnson & Johnson - Pipeline by Stage of Development, 2016
  • Johnson & Johnson - Monotherapy Products in Pipeline, 2016
  • Johnson & Johnson - Combination Treatment Modalities in Pipeline, 2016
  • Johnson & Johnson - Partnered Products in Pipeline, 2016
  • Johnson & Johnson - Out-Licensed Products in Pipeline, 2016
  • Johnson & Johnson - Pipeline by Top 10 Target, 2016
  • Johnson & Johnson - Pipeline by Top 10 Route of Administration, 2016
  • Johnson & Johnson - Pipeline by Top 10 Molecule Type, 2016
  • Johnson & Johnson - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top